07.12.2021 · The average 12 month price objective among analysts that have covered the stock in the last year is $123.36. Several brokerages have weighed in on BPMC. Morgan Stanley lifted their price objective on Blueprint Medicines from $96.00 to $111.00 and gave the company an "equal weight" rating in a report on Friday, October 29th.
Based on 10 Wall Street analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $125.44 with a ...
Oct 30, 2021 · David Lebovitz analyst at Morgan Stanley reiterates coverage on Blueprint Medicines (BPMC) in the Healthcare sector with a Buy rating. TipRanks.com has Fein rated as a 4.7 star analyst with a 50% return on investment and a 18.1% success rate. Lebovitz has set a price target of $111.
What predictions are top-rated research analysts making about Blueprint Medicines (NASDAQ:BPMC)? View BPMC's most recent analyst ratings, analyst estimates, ...
09.11.2021 · Blueprint Medicinesis a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease.
30.10.2021 · David Lebovitz analyst at Morgan Stanley reiterates coverage on Blueprint Medicines (BPMC) in the Healthcare sector with a Buy rating. TipRanks.com has Fein rated as a 4.7 star analyst with a 50% return on investment and a 18.1% success rate.Lebovitz has set a price target of $111. TipRanks.com reports that Blueprint Medicines currently has 6 analysts offering …
Oct 29, 2021 · In recent trading, shares of Blueprint Medicines Corp (Symbol: BPMC) have crossed above the average analyst 12-month target price of $110.33, changing hands for $113.47/share. When a stock reaches ...
Blueprint Medicines Corporation is followed by the analysts listed on this page. Please note that any opinions, estimates or forecasts regarding Blueprint ...
28.07.2021 · About Blueprint Medicines Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease.
21.12.2021 · According to Zacks, analysts expect that Blueprint Medicines will report full year earnings of ($6.31) per share for the current financial year, with EPS estimates ranging from ($6.46) to ($6.07). For the next year, analysts anticipate that the firm will post earnings of ($5.86) per share, with EPS estimates ranging from ($7.20) to ($5.05).
Blueprint Medicines Corporation is followed by the analysts listed on this page. Please note that any opinions, estimates or forecasts regarding Blueprint Medicines Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Blueprint Medicines Corporation or its management.
Dec 07, 2021 · The company had revenue of $24.19 million during the quarter, compared to analyst estimates of $42.58 million. Blueprint Medicines had a negative net margin of 383.58% and a negative return on equity of 30.19%. Blueprint Medicines's revenue was down 96.8% on a year-over-year basis.
6 hours ago · Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing ...
Dec 24, 2021 · According to the issued ratings of 9 analysts in the last year, the consensus rating for Blueprint Medicines stock is Buy based on the current 3 hold ratings, 5 buy ratings and 1 strong buy rating for BPMC. The average twelve-month price target for Blueprint Medicines is $123.78 with a high price target of $151.00 and a low price target of $95 ...
29.10.2021 · There are 9 different analyst targets within the Zacks coverage universe contributing to that average for Blueprint Medicines Corp, but the average is just that — a mathematical average. There are...
29.11.2021 · The Investor Relations website contains information about Blueprint Medicines Corp.'s business for stockholders, potential investors, and financial analysts.
Analyst Price Target is. $123.78. +11.54% Upside Potential. This price target is based on 9 analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $123.78, with a high forecast of $151.00 and a low forecast of $95.00.